MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Majhail, 2015, Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era, Biol Blood Marrow Transplant, 21, 142, 10.1016/j.bbmt.2014.10.001 Hahn, 2015, Establishment of definitions and review process for consistent adjudication of cause-specific mortality after allogeneic unrelated-donor hematopoietic cell transplantation, Biol Blood Marrow Transplant, 21, 1679, 10.1016/j.bbmt.2015.05.019 Anasetti, 2012, Peripheral-blood stem cells versus bone marrow from unrelated donors, N Engl J Med, 367, 1487, 10.1056/NEJMoa1203517 Deeg, 2007, How I treat refractory acute GVHD, Blood, 109, 4119, 10.1182/blood-2006-12-041889 MacMillan, 2010, The best endpoint for acute GVHD treatment trials, Blood, 115, 5412, 10.1182/blood-2009-12-258442 Saliba, 2012, Prognostic value of response after upfront therapy for acute GVHD, Bone Marrow Transplant, 47, 125, 10.1038/bmt.2011.41 Levine, 2015, A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study, Lancet Haematol, 2, e21, 10.1016/S2352-3026(14)00035-0 Hartwell, 2017, An early-biomarker algorithm predicts lethal graft-versus-host disease and survival, JCI Insight, 2, e89798, 10.1172/jci.insight.89798 Harris, 2016, International, multicenter standardization of acute graft-versus-host disease clinical data collection: A report from the Mount Sinai Acute GVHD International Consortium, Biol Blood Marrow Transplant, 22, 4, 10.1016/j.bbmt.2015.09.001 MacMillan, 2015, A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality, Biol Blood Marrow Transplant, 21, 761, 10.1016/j.bbmt.2015.01.001 Armand, 2014, Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation, Blood, 123, 3664, 10.1182/blood-2014-01-552984 Ferrara, 2011, Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease, Blood, 118, 6702, 10.1182/blood-2011-08-375006 Vander Lugt, 2013, ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death, N Engl J Med, 369, 529, 10.1056/NEJMoa1213299 Reynolds, 2006, Clustering rules: a comparison of partitioning and hierarchical clustering algorithms, J Math Model Algorithms, 5, 475, 10.1007/s10852-005-9022-1 Robin, 2011, pROC: an open-source package for R and S+ to analyze and compare ROC curves, BMC Bioinformatics, 12, 77, 10.1186/1471-2105-12-77 MacMillan, 2002, Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems, Biol Blood Marrow Transplant, 8, 387, 10.1053/bbmt.2002.v8.pm12171485 Martin, 2012, First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 18, 1150, 10.1016/j.bbmt.2012.04.005 Levine, 2010, Graft-versus-host disease treatment: predictors of survival, Biol Blood Marrow Transplant, 16, 1693, 10.1016/j.bbmt.2010.05.019 Zhang, 2015, ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease, Sci Transl Med, 7, 308ra160, 10.1126/scitranslmed.aab0166 Jagasia, 2012, Risk factors for acute GVHD and survival after hematopoietic cell transplantation, Blood, 119, 296, 10.1182/blood-2011-06-364265 Mehta, 2016, Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection, Virulence, 7, 901, 10.1080/21505594.2016.1208866 Matsumura-Kimoto, 2016, Association of cumulative steroid dose with risk of infection after treatment for severe acute graft-versus-host disease, Biol Blood Marrow Transplant, 22, 1102, 10.1016/j.bbmt.2016.02.020 Miller, 2017, Infectious risk after allogeneic hematopoietic cell transplantation complicated by acute graft-versus-host disease, Biol Blood Marrow Transplant, 23, 522, 10.1016/j.bbmt.2016.12.630 Bolaños-Meade, 2014, Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802, Blood, 124, 3221, 10.1182/blood-2014-06-577023 Rotz, 2017, ST2 and endothelial injury as a link between GVHD and microangiopathy, N Engl J Med, 376, 1189, 10.1056/NEJMc1700185 Dietrich, 2013, Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment, Biol Blood Marrow Transplant, 19, 22, 10.1016/j.bbmt.2012.09.018 Penack, 2011, The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation, Blood, 117, 4181, 10.1182/blood-2010-10-312934 McDonald, 2017, Predictive value of clinical findings and plasma biomarkers after fourteen days of prednisone treatment for acute graft-versus-host disease, Biol Blood Marrow Transplant, 23, 1257, 10.1016/j.bbmt.2017.04.029 Levine, 2012, Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study, Blood, 119, 3854, 10.1182/blood-2012-01-403063 Hockenbery, 2007, A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease, Blood, 109, 4557, 10.1182/blood-2006-05-021139